Cisplatin + Carboplatin + Etoposide + Durvalumab + Ceralasertib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive Stage Small Cell Lung Cancer
Conditions
Extensive Stage Small Cell Lung Cancer
Trial Timeline
Apr 20, 2021 → Nov 1, 2026
NCT ID
NCT04699838About Cisplatin + Carboplatin + Etoposide + Durvalumab + Ceralasertib
Cisplatin + Carboplatin + Etoposide + Durvalumab + Ceralasertib is a phase 2 stage product being developed by AstraZeneca for Extensive Stage Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04699838. Target conditions include Extensive Stage Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04699838 | Phase 2 | Recruiting |
Competing Products
20 competing products in Extensive Stage Small Cell Lung Cancer